Crossmark

ASO Author Reflections: Survival of Patients with HER2-Positive Breast Cancer After Neoadjuvant Chemotherapy Based on Presenting Clinical Stage and Response to Neoadjuvant Chemotherapy

Crossref DOI link: https://doi.org/10.1245/s10434-025-18188-7

Published Online: 2025-08-20

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tashjian, Nara L.

Hoskin, Tanya L.

Leon-Ferre, Roberto A.

Boughey, Judy C. https://orcid.org/0000-0003-3820-3228
License Information

Text and Data Mining valid from 2025-08-20

Version of Record valid from 2025-08-20
More Information

Article History

Received: 5 August 2025

Accepted: 6 August 2025

First Online: 20 August 2025

Disclosure

: Nara L. Tashjian, Tanya L. Hoskin, Roberto A. Leon-Ferre, and Judy C. Boughey, MD have no disclosures relevant to this manuscript. Judy C. Boughey receives research support, paid to her institution, from Eli Lilly and SymBioSis and is a member of the Data Safety Monitoring Board for Cairns Surgical. She has also received honoraria for speaking for PER, PeerView, and EndoMag, and has contributed a chapter to UpToDate. Roberto A. Leon-Ferre reports consulting fees, paid to Mayo Clinic, from Gilead Sciences, AstraZeneca, Merck, and Lyell Immunopharma, and fees for continuing medical education activities from MJH Life Sciences.

Document is current

Any future updates will be listed below